Disaster Lit® Database Daily Updates

IMPROVING ACCESS TO DISASTER HEALTH INFORMATION
Disaster Information Management Research Center
National Library of Medicine | National Institutes of Health
Having trouble viewing this email? View it as a Web page. Bookmark and Share

You are subscribed to Disaster Lit® Database Daily Updates from the Disaster Information Management Research Center. This information has recently been updated, and is now available.

03/30/2020 12:00 AM EDT

Source: Imperial College London. Published: 3/30/2020. This 35-page report uses a semi-mechanistic Bayesian hierarchical model to attempt to infer the impact of non-pharmaceutical interventions on COVID-19 across 11 European countries. It details why it is critical that the current interventions remain in place, and trends in cases and deaths are closely monitored in the coming days and weeks to provide reassurance that transmission of SARS-Cov-2 is slowing. (PDF)
03/29/2020 12:00 AM EDT

Source: U.S. Food and Drug Administration (FDA). Published: 3/29/2020. This three-page fact sheet informs healthcare personnel of the significant known and potential risks and benefits of the emergency use of decontaminated N95 or N95-equivalent respirators. These compatible N95 or N95-equivalent respirators have been decontaminated using the Battelle CCDS Critical Care Decontamination System™. The document is for healthcare personnel who have been given a decontaminated N95 or N95- equivalent respirator that has been decontaminated using a decontamination system for reuse by healthcare personnel in a healthcare setting to help prevent healthcare personnel exposure to pathogenic biologic airborne particulates during the COVID-19 pandemic. (PDF)
03/28/2020 12:00 AM EDT

Source: World Health Organization (WHO). Published: 3/28/2020. This 120-page document is the first edition of the practical manual to set up and manage a severe acute respiratory infection (SARI) treatment center and a SARI screening facility in healthcare facilities. It has been developed to meet the operational needs emerging with the COVID-19 pandemic. (PDF)
03/28/2020 12:00 AM EDT

Source: U.S. Food and Drug Administration (FDA). Published: 3/28/2020. This seven-page document provides information about the U.S. Food and Drug Administration (FDA)'s issuing of an Emergency Use Authorization (EUA) to permit the emergency use of chloroquine phosphate supplied from the Strategic National Stockpile to treat adults and adolescents who weigh 50 kg or more and are hospitalized with COVID-19 for whom a clinical trial is not available, or participation is not feasible. (PDF)
03/27/2020 12:00 AM EDT

Source: U.S. Food and Drug Administration (FDA). Published: 3/27/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the NxTAG CoV Extended Panel Assay, which received an Emergency Use Authorization from the Food and Drug Administration on March 27, 2020. The NxTAG CoV Extended Panel Assay is authorized for use on using respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
03/27/2020 12:00 AM EDT

Source: American Society of Health-Systems Pharmacists (ASHP). Published: 3/27/2020. The information in this 24-page evidence table is emerging and rapidly evolving because of ongoing research and is subject to the professional judgment and interpretation of the practitioner due to the uniqueness of each medical facility’s approach to the care of patients with COVID-19 and the needs of individual patients. This evidence table is provided to help practitioners better understand current approaches related to treatment and care. (PDF)
03/27/2020 12:00 AM EDT

Source: Centers for Disease Control and Prevention, Center for Preparedness and Response (CDC CPR). Published: 3/27/2020. In this one-hour Clinician Outreach and Communication Activity (COCA) call, presenters focus on current information about people who are higher risk for COVID-19 complications because of their age or underlying medical conditions, particularly those that are not well-controlled. (Video or Multimedia)
03/27/2020 12:00 AM EDT

Source: World Health Organization (WHO). Published: 3/27/2020. This three-page document, updated March 29, 2020, discusses modes of transmission of the virus causing COVID-19, and why the World Health Organization continues to recommend droplet and contact precautions for those people caring for COVID-19 patients, and contact and airborne precautions for circumstances and settings in which aerosol-generating procedures are performed. (PDF)
03/27/2020 12:00 AM EDT

Source: United Nations Office for the Coordination of Humanitarian Affairs, Inter-Agency Standing Committee (IASC). Published: 3/27/2020. This six-page document, developed with the World Health Organization, has a series of messages about COVID-19 that aim at addressing the specific issues of persons deprived of their liberty with the responsible services and ministries. It includes measures to take to prevent outbreaks in detention centers. (PDF)
03/27/2020 12:00 AM EDT

Source: U.S. Food and Drug Administration (FDA). Published: 3/27/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the ID NOW COVID-19, which received an Emergency Use Authorization from the Food and Drug Administration on March 27, 2020. The ID NOW COVID-19 is authorized for use on respiratory specimens collected from individuals who are suspected of COVID-19 by their healthcare provider. (PDF)
03/26/2020 12:00 AM EDT

Source: National Highway Traffic Safety Administration, Office of Emergency Medical Services (EMS). Published: 3/26/2020. In this 55-minute presentation, panelists discuss why crisis standards of care planning is so critical in the pre-hospital setting, especially in the context of COVID-19; how one state prepares for a surge in demand for EMS services; and the implications for local EMS leaders who may have to implement crisis standards of care in their communities. (Video or Multimedia)
03/26/2020 12:00 AM EDT

Source: International Pharmaceutical Federation (FIP). Published: 3/26/2020. The purpose of this 14-page document is to provide relevant clinical information and treatment guidelines on the COVID-19 pandemic for pharmacists and the pharmacy workforce, both in a primary care context (i.e., community pharmacies and primary healthcare facilities) and in hospital settings, as well as for pharmacists working as clinical biologists in medical analysis laboratories, for example, as clinical biologists, and offer a set of references that may be consulted for more information. (PDF)
03/26/2020 12:00 AM EDT

Source: Duke University. Published: 3/26/2020. This seven-page report describes how Duke University has found that the use of hydrogen peroxide vapor results in successful decontamination of commercially available N95 respirators. It discusses the decontamination validation process and post‐decontamination performance validation conducted at Duke. The university believes that N95 sparing and reuse practices are important but not sufficient given the current COVID-19 pandemic, and will begin reuse after decontamination using hydrogen peroxide vapor on a large scale. (PDF)
03/26/2020 12:00 AM EDT

Source: U.S. Food and Drug Administration (FDA). Published: 3/26/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the Real-Time Fluorescent RT-PCR Kit for Detecting SARS-2019-nCoV, which received an Emergency Use Authorization from the Food and Drug Administration on March 26, 2020. The Real-Time Fluorescent RT-PCR Kit for Detecting SARS-2019-nCoV is authorized for use on using respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
03/26/2020 12:00 AM EDT

Source: Harvard University, Harvard T.H. Chan School of Public Health. Published: 3/26/2020. From a significant lag in testing for COVID-19 to a predicted mismatch between patients and available hospital beds, the U.S. healthcare system is under tremendous pressure. This 35-minute Facebook Live Q&A discusses why the U.S. is behind other countries and how innovations may help address the gap. (Video or Multimedia)
03/25/2020 12:00 AM EDT

Source: American Public Health Association (APHA). Published: 3/25/2020. This one-hour, 25-minute webinar is the first in a COVID-19 Conversations series, co-sponsored with the National Academy of Medicine. Public health, medical, and emergency experts share the science on social distancing, as well as strategies to support it. Speakers explore how findings from past pandemics — as well as the current one — can shape responses today. (Video or Multimedia)
03/25/2020 12:00 AM EDT

Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 3/25/2020. This guidance for screening dialysis patients for COVID-19 provides information for Key Concepts; Screen Patients for COVID-19 at Intake; Considerations for Staff; and After a Patient is Screened. (Text)
03/25/2020 12:00 AM EDT

Source: U.S. Food and Drug Administration (FDA). Published: 3/25/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the AvellinoCoV2, which received an Emergency Use Authorization from the Food and Drug Administration on March 25, 2020. The AvellinoCoV2 is authorized for use on using respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
03/24/2020 12:00 AM EDT

Source: Dart Center for Journalism and Trauma [Columbia University]. Published: 3/24/2020. Presenters in this 43-minutes webinar discuss how local and regional reporting can make a difference in the COVID-19 pandemic, what ground-level indicators and issues should be followed, and how reporters can effectively assess local and state-level responses, and accurately cover the pandemic’s impact on families and children. (Video or Multimedia)
03/24/2020 12:00 AM EDT

Source: U.S. Food and Drug Administration (FDA). Published: 3/24/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the PerkinElmer New Coronavirus Nucleic Acid Detection Kit, which received an Emergency Use Authorization from the Food and Drug Administration on March 24, 2020. The PerkinElmer New Coronavirus Nucleic Acid Detection Kit is authorized for use on using respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
03/24/2020 12:00 AM EDT

Source: National Association of County and City Health Officials (NACCHO). Published: 3/24/2020. This 55-minute webinar discusses the Kansas Health Institute's Health Impact Checklist (HI-C). The HI-C uses a combination of checklists and written responses to explicitly connect questions about social, economic, and environmental conditions with questions about potential health impacts and impacts on populations. The tool also guides users to create practical recommendations. (Video or Multimedia)
03/23/2020 12:00 AM EDT

Source: United Nations Population Fund (UNFPA). Published: 3/23/2020. This 13-page report aims to provide practical support to gender-based violence (GBV) practitioners to adapt GBV case management service delivery models quickly and ethically during the current COVID-19 pandemic. GBV programming from other contexts of severely restricted access, such as conflict and natural disaster, offers important insights into how the provision of remote GBV case management support may be adapted to continue to offer a critical avenue of support to vulnerable women and girls. (PDF)
03/23/2020 12:00 AM EDT

Source: U.S. Food and Drug Administration (FDA). Published: 3/23/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the BioFire COVID-19 Test, which received an Emergency Use Authorization from the Food and Drug Administration on March 23, 2020. The BioFire COVID-19 Test is authorized for use on using respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
03/23/2020 12:00 AM EDT

Source: U.S. Food and Drug Administration (FDA). Published: 3/23/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the Accula SARS-CoV-2 Test, which received an Emergency Use Authorization from the Food and Drug Administration on March 23, 2020. The Accula SARS-CoV-2 Test is authorized for use on using respiratory specimens collected from patients suspected of COVID-19 by their healthcare provider. (PDF)
03/20/2020 12:00 AM EDT

Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 3/20/2020. During a large-scale public health emergency involving a respiratory disease like COVID-19, federal, state, or local stockpiled ventilators should be deployed in a way that optimizes the effectiveness, efficiency, and equity of this scarce resource. State and local planners can use the strategies in this guide to assist them when allocating ventilators from public health stockpiles to hospitals and other facilities during a pandemic. (Text)
03/14/2020 12:00 AM EDT

Source: American College of Emergency Physicians (ACEP). Published: 3/14/2020. This two-page chart from the Royal London Hospital details the steps to reduce staff exposure, reduce kit contamination, reduce aerosol generation, and maximize the first pass intubation in the context of the COVID-19 pandemic. (PDF)
03/01/2020 12:00 AM EST

Source: National Academies Press (NAP). Published: 3/2020. In response to a request from the Office of Science and Technology Policy (OSTP), the National Academies of Sciences, Engineering, and Medicine convened a standing committee of experts to help inform OSTP on critical science and policy issues related to emerging infectious diseases and other public health threats, including the COVID-19 pandemic. A previous Rapid Expert Consultation, dated March 15, 2020, provided feedback concerning issues of COVID-19 virus survival on surfaces and in the air, and virus/disease incubation period. This 10-page publication provides an update and elaboration on these issues, as well as some caveats about the work performed so far and as yet unmet needs. (Text)
03/01/2020 12:00 AM EST

Source: National Association of Social Workers (NASW). Published: 3/2020. This three-page document lists actions social workers should take before providing telemental health services. In light of the COVID-19 public health emergency, some states (e.g., Massachusetts, Iowa, and Indiana) are temporarily suspending some of their regulatory provisions for telemental health requirements. Check with each state to find out if any changes have been made to those regulations. (PDF)
03/01/2020 12:00 AM EST

Source: Social Science in Humanitarian Action. Published: 3/2020. This eight-page brief sets out key considerations for protecting informal urban settlements from the spread and impacts of COVID-19. There is heightened concern about these settings because of the combination of population density and limited infrastructure. This briefing discusses what is known about vulnerabilities and how to support local action. (PDF)

Bookmark and Share